|
|
| General |
| Study Status |
Delayed |
Application Number /
Requirement Number |
P130018 / PAS001 |
| Date Original Protocol Accepted |
11/02/2016
|
| Date Current Protocol Accepted |
|
| Study Name |
ProAct Post-Approval Study
|
| Device Name |
PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN
|
| Clinical Trial Number(s) |
NCT00277095
|
| General Study Protocol Parameters |
| Study Design |
Prospective Cohort Study
|
| Data Source |
New Data Collection
|
| Comparison Group |
No Control
|
| Analysis Type |
Descriptive
|
| Study Population |
Adult: >21
|
| Detailed Study Protocol Parameters |
| Study Objectives |
The ProACT PAS is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
|
| Study Population |
Inclusion Criteria
1. Subject is a male of at least 50 years of age.
2. Subject demonstrates stress urinary incontinence.
3. Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
4. Subject is willing and able to undergo surgical implantation of ProACT devices.
5. Subject is willing and able to comply with study-required
follow-up activities, including annual telephonic follow –up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.
6. Subject is willing and able to sign the approved informed consent.
7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
8. Subject has a negative urine culture.
9. Subject has no known urogenital malignancy, other than previously treated prostate cancer.
10. Subject meets ONE of the following criteria:
a. Baseline PSA less than or equal to 2.5ng/mL;
b. Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
11. Physician determines subject to be a suitable surgical candidate.
Exclusion Criteria
1. Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
2. Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
3. Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
4. Subject has undergone radiation therapy in the prostatic area within the last 12 months.
5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
6. Subject has an atonic bladder.
7. Subject had, presently has, or is suspected of having bladder cancer.
8. Subject has untreated or unsuccessfully treated bladder stones.
9. Subject has detrusor sphincter dyssynergia.
10. Subject has known hemophilia or a bleeding disorder.
11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.
|
| Sample Size |
145 subjects will be enrolled at 5 to 7 clinical sites in the U.S.
|
| Key Study Endpoints |
1. Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up.
2. Cumulative incidence of ProACT device erosions over 5 years of follow-up.
3. Incontinence Quality of Life Questionnaire (I-QoL) over 5 year of follow-up.
4. Choice of subsequent SUI therapy(ies) post ProACT treatment.
|
| Follow-up Visits and Length of Follow-up |
5 years
|
